INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic
This site is intended for US healthcare professionals only.
Full Prescribing InformationMedication GuideRequest a Representative
phone
1-844-4RYTELO
RYTELO (imetelstat) logo
PIMG

Support for your patients to
access RYTELO

1-844-4RYTELO |
Monday to Friday 8:00 AM-8:00 PM ET
(Except major holidays)

Support for your
patients to access RYTELO

1-844-4RYTELO
Monday to Friday 8:00 AM-8:00 PM ET
(Except major holidays)

REACH4RYTELO Patient
Support Program

The REACH4RYTELO Patient Support Program helps your patients who have been prescribed RYTELO navigate access and reimbursement.*
benefits investigation
Benefits investigation: support during the process of determining a patient’s insurance benefits for RYTELO and eligibility for affordability programs
prior authorization
Prior Authorization (PA): provide information relevant to navigating the PA approval process from the patient’s insurance company
appeals support
Appeals Support: provide information relevant to navigating appeals of any denied PA requests.

Getting started with REACH4RYTELO

1.
Download the REACH4RYTELO Patient Enrollment Form.
2.
Complete the form with your patient and submit via fax or email. A completed form includes signatures from both the patient and the healthcare provider.
download patient enrollment form
Download the REACH4RYTELO Patient Enrollment Form
fax
Fax: 1-888-224-2518
email
Once your patient has been enrolled in REACH4RYTELO and their benefits investigation has been conducted, you will receive a summary of the results of the benefits investigation.* If information is missing a Case Manager will follow up with you.
Please respond promptly to a request for further information from a Case Manager to avoid any delays.
*The accurate completion of reimbursement- or coverage-related documentation is the responsibility of the healthcare provider and patient. REACH4RYTELO and its agents make no guarantee regarding coverage and reimbursement for RYTELO.
bg-leftbg-right

The REACH4RYTELO Copay Program

For eligible, commercially insured patients, the REACH4RYTELO Copay Program offers savings up to $10,650 per calendar year.† There are no income requirements to participate in the program.
Terms and conditions apply. See patient copay program brochure for full terms and conditions.
out of pocket
If eligible, patients may pay as little as $0 out-of-pocket for RYTELO, which includes copay and coinsurance, up to $9450 annually.
savings
If eligible, patients may save up to $100 per infusion, up to $1200 annually. Itemized explanation of benefits (EOB) must have separate line for out-of-pocket cost of administration.

How to apply for the REACH4RYTELO Copay Program

If you determine RYTELO is right for your patient, download the REACH4RYTELO Patient Enrollment Form or call 1-844-4RYTELO (1-844-479-8356).† Complete the form with your patient and submit via fax or email.
fax
Fax: 1-888-224-2518
email
Email: Support@REACH4RYTELO.com
Once the patient has been enrolled in REACH4RYTELO, a Case Manager will evaluate their Copay Program eligibility.
†The REACH4RYTELO Copay Program is not available to patients with any form of government insurance (such as Medicaid, Medicare, TRICARE, and VA). Patients must meet certain eligibility criteria to qualify for this program, including requirements related to the diagnosis for which the patient is receiving treatment and the patient’s insurance status. To enroll in the Copay Program, patients must first enroll in REACH4RYTELO. If eligible for the Copay Program, the patient may pay as little as $0 out-of-pocket for RYTELO with a maximum benefit of $9450 per year for the cost of the drug and a maximum benefit of $1200 per year for the cost of administration (up to $100 per infusion). An itemized EOB must be provided with a separate line for the out-of-pocket cost of administration fee. Residents of MA, MI, MN, and RI are not eligible to receive copay assistance for product administration and are therefore only eligible for a maximum benefit of $9450 per year for the cost of the drug. For Copay Program eligibility questions, contact a representative from REACH4RYTELO at 1-844-479-8356.

All programs provided through REACH4RYTELO are subject to eligibility requirements. Geron reserves the right to modify or discontinue REACH4RYTELO at any time without notice.
download patient copay program brochure
Download Patient Copay Program Brochure
logo-small

Call us at 1-844-4RYTELO
to get support today!

Monday to Friday 8:00 AM-8:00 PM ET
(Except major holidays)
carot

INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombocytopenia
RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.
carot

INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).

IMPORTANT SAFETY INFORMATION

WARNINGS AND PRECAUTIONS

Thrombocytopenia
RYTELO can cause thrombocytopenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased platelets occurred in 65% of patients with MDS treated with RYTELO.
Monitor patients with thrombocytopenia for bleeding. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer platelet transfusions as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.
Neutropenia
RYTELO can cause neutropenia based on laboratory values. In the clinical trial, new or worsening Grade 3 or 4 decreased neutrophils occurred in 72% of patients with MDS treated with RYTELO.
Monitor patients with Grade 3 or 4 neutropenia for infections, including sepsis. Monitor complete blood cell counts prior to initiation of RYTELO, weekly for the first two cycles, prior to each cycle thereafter, and as clinically indicated. Administer growth factors and anti-infective therapies for treatment or prophylaxis as appropriate. Delay the next cycle and resume at the same or reduced dose, or discontinue as recommended.
Infusion-Related Reactions
RYTELO can cause infusion-related reactions. In the clinical trial, infusion-related reactions occurred in 8% of patients with MDS treated with RYTELO; Grade 3 or 4 infusion-related reactions occurred in 1.7%, including hypertensive crisis (0.8%). The most common infusion-related reaction was headache (4.2%). Infusion-related reactions usually occur during or shortly after the end of the infusion.
Premedicate patients at least 30 minutes prior to infusion with diphenhydramine and hydrocortisone as recommended and monitor patients for one hour following the infusion as recommended. Manage symptoms of infusion-related reactions with supportive care and infusion interruptions, decrease infusion rate, or permanently discontinue as recommended.
Embryo-Fetal Toxicity
RYTELO can cause embryo-fetal harm when administered to a pregnant woman. Advise pregnant women of the potential risk to a fetus. Advise females of reproductive potential to use effective contraception during treatment with RYTELO and for 1 week after the last dose.

ADVERSE REACTIONS

Serious adverse reactions occurred in 32% of patients who received RYTELO. Serious adverse reactions in >2% of patients included sepsis (4.2%), fracture (3.4%), cardiac failure (2.5%), and hemorrhage (2.5%). Fatal adverse reactions occurred in 0.8% of patients who received RYTELO, including sepsis (0.8%).
Most common adverse reactions (≥10% with a difference between arms of >5% compared to placebo), including laboratory abnormalities, were decreased platelets, decreased white blood cells, decreased neutrophils, increased AST, increased alkaline phosphatase, increased ALT, fatigue, prolonged partial thromboplastin time, arthralgia/myalgia, COVID-19 infections, and headache.

INDICATION

RYTELO™ (imetelstat) is indicated for the treatment of adult patients with low- to intermediate-1 risk myelodysplastic syndromes (MDS) with transfusion-dependent anemia requiring 4 or more red blood cell units over 8 weeks who have not responded to or have lost response to or are ineligible for erythropoiesis-stimulating agents (ESA).
Please see full Prescribing Information and Medication Guide.